- 全部删除
您的购物车当前为空
IBL-302 (AMU302) 是一种口服有效的PIM和PI3K/AKT/mTOR双信号抑制剂,具有抗乳腺癌和成神经细胞瘤的活性。在裸鼠异种移植模型中,IBL-302 显示出体内效力,并能抑制曲妥珠单抗的耐药性问题。此外,IBL-302 还能增强顺铂、阿霉素和依托泊苷等常见细胞毒性化疗药物的效果。

IBL-302 (AMU302) 是一种口服有效的PIM和PI3K/AKT/mTOR双信号抑制剂,具有抗乳腺癌和成神经细胞瘤的活性。在裸鼠异种移植模型中,IBL-302 显示出体内效力,并能抑制曲妥珠单抗的耐药性问题。此外,IBL-302 还能增强顺铂、阿霉素和依托泊苷等常见细胞毒性化疗药物的效果。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
IBL-302 相关产品
| 产品描述 | IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3]. |
| 别名 | AMU302 |
| 分子量 | 567.64 |
| 分子式 | C25H18FN5O4S3 |
| CAS No. | 1414455-21-2 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容